200 related articles for article (PubMed ID: 7745107)
21. Orally active iron chelators.
Merson L; Olivier N
Blood Rev; 2002 Jun; 16(2):127-34. PubMed ID: 12127956
[TBL] [Abstract][Full Text] [Related]
22. Deferiprone as an oral iron chelator in sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
[TBL] [Abstract][Full Text] [Related]
23. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).
Addis A; Loebstein R; Koren G; Einarson TR
Eur J Clin Pharmacol; 1999 Mar; 55(1):1-6. PubMed ID: 10206077
[TBL] [Abstract][Full Text] [Related]
24. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
Kontoghiorghes GJ
Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
[TBL] [Abstract][Full Text] [Related]
25. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
[TBL] [Abstract][Full Text] [Related]
26. Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.
Kim CM; Shin SH
J Korean Med Sci; 2009 Apr; 24(2):289-95. PubMed ID: 19399272
[TBL] [Abstract][Full Text] [Related]
27. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
Pootrakul P; Breuer W; Sametband M; Sirankapracha P; Hershko C; Cabantchik ZI
Blood; 2004 Sep; 104(5):1504-10. PubMed ID: 15155464
[TBL] [Abstract][Full Text] [Related]
28. Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates.
Turcot I; Stintzi A; Xu J; Raymond KN
J Biol Inorg Chem; 2000 Oct; 5(5):634-41. PubMed ID: 11085654
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of deferiprone in the treatment of acute iron intoxication in rats.
Fassos FF; Berkovitch M; Daneman N; Koren L; Cameron RG; Klein J; Falcitelli C; St Louis P; Daneman R; Koren G
J Toxicol Clin Toxicol; 1996; 34(3):279-87. PubMed ID: 8667465
[TBL] [Abstract][Full Text] [Related]
30. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.
Rodrat S; Yamanont P; Tankanitlert J; Chantraraksri U; Fucharoen S; Morales NP
Pharmacology; 2012; 90(1-2):88-94. PubMed ID: 22759897
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of oral deferiprone in acute iron poisoning.
Berkovitch M; Livne A; Lushkov G; Segal M; Talmor C; Bentur Y; Klein J; Koren G
Am J Emerg Med; 2000 Jan; 18(1):36-40. PubMed ID: 10674529
[TBL] [Abstract][Full Text] [Related]
32. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
[TBL] [Abstract][Full Text] [Related]
34. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
35. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats.
Brissot P; Bolder U; Schteingart CD; Arnaud J; Hofmann AF
Hepatology; 1997 Jun; 25(6):1457-61. PubMed ID: 9185768
[TBL] [Abstract][Full Text] [Related]
36. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
37. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
38. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
39. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Chuansumrit A; Songdej D; Sirachainan N; Wongwerawattanakoon P; Kadegasem P; Sasanakul W
Paediatr Int Child Health; 2016 Aug; 36(3):209-13. PubMed ID: 26052612
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia : Impact of Splenectomy and Iron Status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 27975237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
